Scpharmaceuticals Historical Balance Sheet

SCPH Stock

USD 3.27 0.05 1.51%

Trend analysis of Scpharmaceuticals balance sheet accounts such as Other Liabilities of 9.1 M, Net Tangible Assets of 54.8 M, Property Plant And Equipment Net of 1 M or Accounts Payable of 4.8 M provides information on Scpharmaceuticals' total assets, liabilities, and equity, which is the actual value of Scpharmaceuticals to its prevalent stockholders. By breaking down trends over time using Scpharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Scpharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Scpharmaceuticals is a good buy for the upcoming year.

Scpharmaceuticals Inventory

10.67 Million

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.

About Scpharmaceuticals Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Scpharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Scpharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Scpharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Scpharmaceuticals currently owns. An asset can also be divided into two categories, current and non-current.

Scpharmaceuticals Balance Sheet Chart

As of now, Scpharmaceuticals' Accounts Payable is increasing as compared to previous years. The Scpharmaceuticals' current Cash is estimated to increase to about 75.7 M, while Total Assets are projected to decrease to under 90.6 M.

Total Assets Other Current Liab Total Current Liabilities Other Liab Capital Stock

Add Fundamental

Total Assets

Total assets refers to the total amount of Scpharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Scpharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Scpharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Scpharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Capital Stock

The total amount of a company's capital funded by shareholders through the issue and subscription of shares.

Most accounts from Scpharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Scpharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Scpharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.As of now, Scpharmaceuticals' Accounts Payable is increasing as compared to previous years. The Scpharmaceuticals' current Cash is estimated to increase to about 75.7 M, while Total Assets are projected to decrease to under 90.6 M.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	4.7M	8.7M	10.0M	10.5M
Total Assets	124.2M	94.5M	108.7M	90.6M

Other Current Liab Total Assets

Scpharmaceuticals balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Surpluse	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Preferred Stock Total Equity	Total Current Assets
Total Assets		0.51	0.73	-0.21	0.54	0.95	0.84	-0.65	-0.8	0.53	0.92	0.88	0.82	0.47	0.99	0.63	0.58	0.19	0.92	0.46	0.64	0.69	0.35	0.64	0.91	1.0
Other Current Liab	0.51		0.72	0.1	0.9	0.44	0.41	0.24	-0.87	0.93	0.26	0.41	0.26	0.0	0.44	0.96	0.83	0.49	0.68	0.92	0.92	0.89	0.62	0.73	0.45	0.51
Total Current Liabilities	0.73	0.72		-0.19	0.61	0.74	0.6	-0.25	-0.89	0.62	0.57	0.62	0.62	0.27	0.68	0.82	0.88	0.23	0.9	0.61	0.87	0.84	0.45	0.66	0.75	0.73
Total Stockholder Equity	-0.21	0.1	-0.19		0.12	-0.15	0.17	0.28	0.19	0.4	-0.24	0.06	-0.51	-0.58	-0.25	0.11	-0.22	0.09	-0.27	0.39	-0.09	-0.1	0.04	0.01	-0.27	-0.22
Other Liab	0.54	0.9	0.61	0.12		0.46	0.42	0.27	-0.84	0.88	0.23	0.41	0.32	-0.17	0.48	0.9	0.76	0.52	0.67	0.87	0.84	0.87	0.62	0.72	0.4	0.55
Net Tangible Assets	0.95	0.44	0.74	-0.15	0.46		0.9	-0.65	-0.75	0.46	0.89	0.93	0.82	0.47	0.94	0.59	0.56	-0.08	0.91	0.45	0.61	0.64	0.1	0.64	0.8	0.95
Property Plant And Equipment Net	0.84	0.41	0.6	0.17	0.42	0.9		-0.58	-0.61	0.53	0.8	0.99	0.59	0.24	0.82	0.51	0.45	0.0	0.76	0.56	0.43	0.44	0.15	0.72	0.76	0.84
Net Debt	-0.65	0.24	-0.25	0.28	0.27	-0.65	-0.58		0.13	0.16	-0.86	-0.64	-0.65	-0.66	-0.71	0.08	0.09	0.24	-0.4	0.24	0.03	-0.01	0.16	-0.08	-0.66	-0.65
Retained Earnings	-0.8	-0.87	-0.89	0.19	-0.84	-0.75	-0.61	0.13		-0.77	-0.57	-0.64	-0.64	-0.23	-0.75	-0.91	-0.89	-0.35	-0.93	-0.76	-0.93	-0.94	-0.54	-0.78	-0.72	-0.8
Accounts Payable	0.53	0.93	0.62	0.4	0.88	0.46	0.53	0.16	-0.77		0.31	0.5	0.15	-0.11	0.46	0.92	0.67	0.53	0.6	0.96	0.81	0.8	0.63	0.7	0.45	0.53
Cash	0.92	0.26	0.57	-0.24	0.23	0.89	0.8	-0.86	-0.57	0.31		0.85	0.82	0.61	0.95	0.4	0.29	-0.04	0.74	0.23	0.43	0.46	0.1	0.48	0.85	0.92
Non Current Assets Total	0.88	0.41	0.62	0.06	0.41	0.93	0.99	-0.64	-0.64	0.5	0.85		0.67	0.32	0.86	0.51	0.46	-0.03	0.8	0.52	0.46	0.47	0.13	0.72	0.8	0.88
Non Currrent Assets Other	0.82	0.26	0.62	-0.51	0.32	0.82	0.59	-0.65	-0.64	0.15	0.82	0.67		0.43	0.85	0.4	0.4	-0.15	0.76	0.16	0.49	0.53	0.01	0.51	0.72	0.82
Other Assets	0.47	0.0	0.27	-0.58	-0.17	0.47	0.24	-0.66	-0.23	-0.11	0.61	0.32	0.43		0.51	0.06	0.16	-0.23	0.4	-0.24	0.21	0.21	-0.15	-0.07	0.42	0.47
Cash And Short Term Investments	0.99	0.44	0.68	-0.25	0.48	0.94	0.82	-0.71	-0.75	0.46	0.95	0.86	0.85	0.51		0.57	0.5	0.14	0.88	0.38	0.59	0.64	0.3	0.59	0.9	0.99
Net Receivables	0.63	0.96	0.82	0.11	0.9	0.59	0.51	0.08	-0.91	0.92	0.4	0.51	0.4	0.06	0.57		0.83	0.39	0.77	0.89	0.97	0.96	0.55	0.73	0.52	0.63
Common Stock Shares Outstanding	0.58	0.83	0.88	-0.22	0.76	0.56	0.45	0.09	-0.89	0.67	0.29	0.46	0.4	0.16	0.5	0.83		0.4	0.83	0.7	0.86	0.84	0.58	0.7	0.59	0.58
Non Current Liabilities Total	0.19	0.49	0.23	0.09	0.52	-0.08	0.0	0.24	-0.35	0.53	-0.04	-0.03	-0.15	-0.23	0.14	0.39	0.4		0.2	0.41	0.32	0.35	0.97	0.21	0.37	0.19
Capital Surpluse	0.92	0.68	0.9	-0.27	0.67	0.91	0.76	-0.4	-0.93	0.6	0.74	0.8	0.76	0.4	0.88	0.77	0.83	0.2		0.58	0.8	0.83	0.4	0.72	0.84	0.92
Inventory	0.46	0.92	0.61	0.39	0.87	0.45	0.56	0.24	-0.76	0.96	0.23	0.52	0.16	-0.24	0.38	0.89	0.7	0.41	0.58		0.77	0.74	0.52	0.82	0.38	0.46
Other Current Assets	0.64	0.92	0.87	-0.09	0.84	0.61	0.43	0.03	-0.93	0.81	0.43	0.46	0.49	0.21	0.59	0.97	0.86	0.32	0.8	0.77		0.99	0.5	0.65	0.54	0.64
Other Stockholder Equity	0.69	0.89	0.84	-0.1	0.87	0.64	0.44	-0.01	-0.94	0.8	0.46	0.47	0.53	0.21	0.64	0.96	0.84	0.35	0.83	0.74	0.99		0.52	0.62	0.56	0.69
Total Liab	0.35	0.62	0.45	0.04	0.62	0.1	0.15	0.16	-0.54	0.63	0.1	0.13	0.01	-0.15	0.3	0.55	0.58	0.97	0.4	0.52	0.5	0.52		0.35	0.52	0.35
Property Plant And Equipment Gross	0.64	0.73	0.66	0.01	0.72	0.64	0.72	-0.08	-0.78	0.7	0.48	0.72	0.51	-0.07	0.59	0.73	0.7	0.21	0.72	0.82	0.65	0.62	0.35		0.6	0.64
Preferred Stock Total Equity	0.91	0.45	0.75	-0.27	0.4	0.8	0.76	-0.66	-0.72	0.45	0.85	0.8	0.72	0.42	0.9	0.52	0.59	0.37	0.84	0.38	0.54	0.56	0.52	0.6		0.91
Total Current Assets	1.0	0.51	0.73	-0.22	0.55	0.95	0.84	-0.65	-0.8	0.53	0.92	0.88	0.82	0.47	0.99	0.63	0.58	0.19	0.92	0.46	0.64	0.69	0.35	0.64	0.91

Click cells to compare fundamentals

Scpharmaceuticals Account Relationship Matchups

Scpharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	109.0M	79.0M	124.2M	94.5M	108.7M	90.6M
Other Current Liab	4.3M	3.5M	4.7M	8.7M	10.0M	10.5M
Total Current Liabilities	9.3M	14.8M	7.4M	13.1M	15.1M	8.3M
Total Stockholder Equity	(161.7M)	(189.7M)	(226.5M)	37.2M	33.5M	35.2M
Other Liab	58K	219K	367K	7.5M	8.7M	9.1M
Net Tangible Assets	51.4M	82.2M	63.1M	72.4M	83.3M	54.8M
Property Plant And Equipment Net	908K	479K	620K	1.5M	1.7M	1.0M
Net Debt	(85.1M)	(56.6M)	(33.7M)	(6.5M)	(7.5M)	(7.9M)
Retained Earnings	(161.7M)	(189.7M)	(226.5M)	(281.3M)	(253.2M)	(240.6M)
Accounts Payable	1.7M	544K	1.5M	4.0M	4.6M	4.8M
Cash	105.3M	74.3M	71.1M	46.8M	53.8M	75.7M
Non Current Assets Total	1.2M	762K	887K	1.5M	1.8M	1.2M
Non Currrent Assets Other	132K	283K	267K	82K	94.3K	159.4K
Other Assets	1.1M	283K	267K	1.0	1.15	1.09
Cash And Short Term Investments	105.3M	75.5M	118.4M	76.0M	87.4M	85.2M
Net Receivables	479K	310K	2.3M	4.5M	5.2M	5.4M
Common Stock Shares Outstanding	24.6M	27.4M	28.4M	38.5M	44.3M	22.2M
Liabilities And Stockholders Equity	(134.8M)	(167.1M)	(174.8M)	94.5M	85.0M	89.3M
Non Current Liabilities Total	17.6M	7.7M	44.3M	44.1M	50.7M	29.9M
Capital Surpluse	180.8M	243.8M	246.2M	298.9M	343.8M	182.1M
Other Current Assets	2.7M	3.0M	2.5M	3.6M	4.1M	4.3M
Other Stockholder Equity	243.8M	246.2M	298.9M	318.6M	366.3M	384.7M
Total Liab	26.9M	22.6M	51.8M	57.3M	65.9M	38.2M
Property Plant And Equipment Gross	93K	649K	808K	1.5M	1.7M	1.8M
Total Current Assets	107.8M	78.3M	123.3M	92.9M	106.9M	89.4M
Accumulated Other Comprehensive Income	(102K)	1K	(1K)	32K	(1.2K)	(1.2K)
Property Plant Equipment	1.3M	908K	69K	54K	48.6K	46.2K
Non Current Liabilities Other	219K	367K	35K	177K	203.6K	147.7K
Short Long Term Debt Total	20.2M	17.6M	37.4M	40.3M	46.3M	24.9M
Long Term Debt	16.9M	7.4M	36.8M	38.8M	44.6M	46.9M
Long Term Debt Total	18.9M	16.9M	7.4M	36.8M	42.3M	44.4M
Capital Lease Obligations	940K	476K	574K	1.5M	1.3M	963.3K
Net Invested Capital	101.4M	73.6M	109.2M	76.0M	68.4M	72.5M
Net Working Capital	98.5M	63.4M	115.9M	79.8M	71.8M	71.8M
Short Term Debt	3.3M	10.8M	1.1M	352K	404.8K	384.6K

Currently Active Assets on Macroaxis

CRM	Salesforce
C	Citigroup
GM	General Motors
WD	Walker Dunlop
MSFT	Microsoft

When determining whether Scpharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Scpharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Scpharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Scpharmaceuticals Stock:

How To Invest In Scpharmaceuticals

Details

Is Scpharmaceuticals Stock a good investment?

Details

What is Scpharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.

You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.95)

Revenue Per Share

0.741

Quarterly Revenue Growth

1.641

Return On Assets

(0.34)

Return On Equity

(2.01)

The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Scpharmaceuticals Historical Balance Sheet

Scpharmaceuticals Inventory

10.67 Million

About Scpharmaceuticals Balance Sheet Analysis

Scpharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Capital Stock

Scpharmaceuticals balance sheet Correlations

Scpharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Scpharmaceuticals balance sheet Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash And Short Term Investments
Other Stockholder Equity	+ 0.99	Other Current Assets
Other Current Assets	+ 0.97	Net Receivables

Other Stockholder Equity	- 0.94	Retained Earnings
Other Current Assets	- 0.93	Retained Earnings
Capital Surpluse	- 0.93	Retained Earnings
Net Receivables	- 0.91	Retained Earnings
Common Stock Shares Outstanding	- 0.89	Retained Earnings
Retained Earnings	- 0.89	Total Current Liabilities